Respiratory Research,
Год журнала:
2023,
Номер
24(1)
Опубликована: Ноя. 6, 2023
Abstract
Background
Right
heart
failure
(RHF)
is
a
complication
of
pulmonary
hypertension
(PH)
and
increases
the
mortality
independently
underlying
disease.
However,
process
RHF
development
progression
not
fully
understood.
We
aimed
to
develop
effective
approaches
for
early
diagnosis
precise
evaluation
RHF.
Methods
ventricle
(RV)
pressure
overload
was
performed
via
artery
banding
(PAB)
surgery
in
Sprague–Dawley
(SD)
rats
induce
Echocardiography,
right
catheterization,
histological
staining,
fibroblast
activation
protein
(FAP)
immunofluorescence
18
F-labelled
FAP
inhibitor-42
([
F]
-FAPI-42)
positron
emission
tomography/computed
tomography
(PET/CT)
were
at
day
3,
week
1,
2,
4
8
after
PAB.
RNA
sequencing
explore
molecular
alterations
between
PAB
sham
group
2
respectively.
Results
RV
hemodynamic
disorders
aggravated,
function
declined
based
on
catheterization
echocardiography
Progressive
cardiac
hypertrophy,
fibrosis
capillary
rarefaction
could
be
observed
from
weeks
indicated
80
upregulated
genes
43
downregulated
both
PAB;
Gene
Ontology
(GO)
analysis
revealed
that
as
most
significant
biological
under
overload.
Immunofluorescence
[
-FAPI-42
PET/CT
FAPI
uptake
significantly
higher
further
increased
Conclusion
progressively
with
prominent
change
overload,
sensitive
accurate
histopathology
evaluation.
Theranostics,
Год журнала:
2022,
Номер
12(4), С. 1557 - 1569
Опубликована: Янв. 1, 2022
In
recent
years,
quinoline-based
fibroblast
activation
protein
(FAP)
inhibitors
(FAPI)
have
shown
promising
results
in
the
diagnosis
of
cancer
and
several
other
diseases,
making
them
hotspot
much
productive
research.
This
review
summarizes
literature
for
state-of-the-art
FAPI-PET
imaging
compared
with
fluorodeoxyglucose
(FDG)-PET.
We
also
summarize
use
therapeutic
regimen
improvement
(FAP)-targeted
molecule
modification
strategies,
as
well
preliminary
clinical
studies
regarding
FAP-targeted
radionuclide
therapy.
Our
qualitative
summary
to
date
can
inform
future
research
directions,
medical
guidelines,
optimal
decision-making.
British Journal of Radiology,
Год журнала:
2022,
Номер
96(1142)
Опубликована: Июль 1, 2022
Fibroblast-activation
protein
(FAP)
is
a
serine
protease
classified
in
the
dipeptidyl
peptidase
4
(DPP4)
family.
FAP
predominantly
expressed
activated
fibroblasts
such
as
cancer-associated
(CAFs).
expression
CAFs
associated
with
tumor
progression
and
poor
prognosis
solid
cancers.
Recently,
radiolabeled
inhibitors
(FAPI)
has
been
developed,
which
enables
positron
emission
tomography
(PET)
imaging
of
FAP.
FAPI
PET/CT
can
provide
higher
tumor-to-background
ratio
(TBR)
than
Abstract
The
discovery
of
fibroblast
activation
protein
inhibitor
positron
emission
tomography
(FAPI-PET)
has
paved
the
way
for
a
new
class
PET
tracers
that
target
tumor
microenvironment
(TME)
rather
than
itself.
Although
18
F-fluorodeoxyglucose
(FDG)
is
most
common
tracer
used
in
clinical
imaging
cancer,
multiple
studies
have
now
shown
family
FAP
ligands
commonly
outperform
FDG
detecting
cancers,
especially
those
known
to
lower
uptake
on
FDG-PET.
Moreover,
FAPI-PET
will
applications
benign
fibrotic
or
inflammatory
conditions.
Thus,
even
while
are
development
and
yet
enter
guidelines,
significant
body
literature
emerged
FAPI-PET,
suggesting
it
important
roles.
This
article
summarizes
current
state
as
well
potential
uses
theranostic
agent.
Fluorine
18
(18F)
fluorodeoxyglucose
(FDG)
positron
emission
tomography/computed
tomography
(PET/CT)
has
limitations
in
staging
hepatocellular
carcinoma
(HCC).
The
recently
introduced
18F-labeled
fibroblast-activation
protein
inhibitor
(FAPI)
shown
promising
prospects
detection
of
HCC
lesions.
This
study
aimed
to
investigate
the
initial
and
restaging
performance
18F-FAPI
PET/CT
compared
18F-FDG
HCC.This
prospective
enrolled
histologically
confirmed
patients
from
March
2021
September
2022.
All
were
examined
with
within
1
week.
maximum
standard
uptake
value
(SUVmax),
tumor-to-background
ratio
(TBR),
diagnostic
accuracy
between
two
modalities.A
total
67
(57
men;
median
age,
57
[range,
32-83]
years
old)
included.
PET
showed
higher
SUVmax
TBR
values
than
intrahepatic
lesions
(SUVmax:
6.7
vs.
4.3,
P
<
0.0001;
TBR:
3.9
1.7,
0.0001).
In
performance,
had
rate
[92.2%
(238/258)
vs
41.1%
(106/258),
0.0001]
lymph
node
metastases
[97.9%
(126/129)
89.1%
(115/129),
=
0.01],
comparable
distant
[63.6%
(42/66)
69.7%
(46/66),
>
0.05].
detected
primary
tumors
16
negative
18F-FDG,
upgraded
T-stages
12
identified
4
true
positive
findings
for
local
recurrence
PET,
leading
planning
therapy
changes
47.8%
(32/67)
patients.18F-FAPI
more
lesions,
HCC,
which
is
helpful
improve
clinical
management
patients.Clinical
Trials,
NCT05485792
.
Registered
August
2022,
Retrospectively
registered.
Cancers,
Год журнала:
2023,
Номер
15(4), С. 1193 - 1193
Опубликована: Фев. 13, 2023
Cancer
represents
a
major
cause
of
death
worldwide
and
is
characterized
by
the
uncontrolled
proliferation
abnormal
cells
that
escape
immune
regulation.
It
now
understood
cancer-associated
fibroblasts
(CAFs),
which
express
specific
fibroblast
activation
protein
(FAP),
are
critical
participants
in
tumor
development
metastasis.
Researchers
have
developed
various
FAP-targeted
probes
for
imaging
different
tumors
from
antibodies
to
boronic
acid-based
inhibitor
molecules
determined
quinoline-based
FAP
inhibitors
(FAPIs)
most
appropriate
candidate
as
radiopharmaceutical
FAPI
PET/CT
imaging.
When
applied
clinically,
yielded
satisfactory
results.
Over
past
few
years,
utility
effectiveness
detection
staging
been
compared
with
FDG
aspects,
including
standardized
uptake
values
(SUVs),
rate
absorbance
clearance.
This
review
summarizes
clinical
application
PET/CT,
emphasizing
diagnosis
management
types
future
prospects
This
study
investigates
the
value
of
fluorine
18
([18F])-labeled
fibroblast
activation
protein
inhibitor
(FAPI)
for
lymph
node
(LN)
metastases
in
patients
with
stage
I-IIIA
non-small
cell
lung
cancer
(NSCLC).
From
November
2021
to
October
2022,
53
NSCLC
who
underwent
radical
resection
were
prospectively
included.
[18F]-fluorodeoxyglucose
(FDG)
and
[18F]FAPI
examinations
performed
within
one
week.
LN
staging
was
validated
using
surgical
pathological
findings.
[18F]FDG
uptake
compared
Wilcoxon
signed-ranks
test.
Furthermore,
diagnostic
nodal
groups
investigated.
In
(median
age,
64
years,
range:
31-76
years),
specificity
detecting
metastasis
significantly
higher
than
that
(P
<
0.001).
High
risk
category,
greater
short-axis
dimension(≥
1.0
cm),
absence
calcification
or
high-attenuation,
FDG
SUVmax
(≥
10.1)
factors
metastasis(P
0.05).
The
concurrence
these
four
accurately
predicted
(Positive
Predictive
Value
[PPV]
100%),
whereas
presence
three
unable
discriminate
nature
LNs
(PPV
21.7%).
Adding
this
circumstance
improved
value.
an
SUVmax<6.2
diagnosed
as
benign
(Negative
93.8%),
SUVmax≥6.2
without
high-attenuation
87.5%).
Ultimately,
integration
PET/CT
resulted
highest
accuracy
N
(83.0%)
clinical
decision
revisions
29
patients.
NSCLC,
contributed
additional
valuable
information
reduce
uncertainties
after
PET/CT.
Integrating
more
precise
decisions.
Chinese
Clinical
Trial
Registry:
ChiCTR2100044944
(Registered:
1
April
2021,
https://www.chictr.org.cn/showprojEN.html?proj=123995
).
Journal of Nuclear Medicine,
Год журнала:
2025,
Номер
66(1), С. 98 - 103
Опубликована: Янв. 1, 2025
The
purpose
of
this
study
was
to
investigate
the
feasibility
using
18F-labeled
fibroblast
activation
protein
inhibitor
(FAPI)
PET/CT
in
assessing
fibrotic
remodeling
pulmonary
artery
(PA)
and
right
ventricle
(RV)
arterial
hypertension
(PAH).
Methods:
In
a
rat
model
monocrotaline-induced
PAH,
rats
were
euthanized
at
different
time
points
for
tissue
analysis
(fibroblast
immunofluorescence
Masson's
trichrome
staining)
after
completing
18F-FAPI
hemodynamic
measurements.
Thirty-eight
PAH
patients
enrolled
participate
imaging,
with
heart
catheterization
echocardiography
performed
within
1
wk
assess
hemodynamics
cardiac
function.
Results:
animal
experiments,
RV
systolic
pressure
monocrotaline
increased
from
day
14
21
injection.
uptake
expression
myocardium
lungs
peaked
on
Collagen
deposition
RVs
peripheral
PAs
progressively
deteriorated
21.
human
study,
imaging
identified
varying
degrees
proximal
distal
PAs,
correlating
clinical,
function,
parameters.
Among
5
follow-up
who
underwent
second
scan
6
mo
(range,
4-9
mo)
PAH-targeted
therapy,
3
demonstrated
reduced
uptake,
corresponding
clinical
improvement.
Conclusion:
is
feasible
visualizing
PA
PAH.
Although
it
offers
promise
disease-related
changes,
its
role
evaluating
disease
severity
monitoring
therapeutic
efficacy
requires
further
investigation.
